Last reviewed · How we verify
NCT06605001: DAISY
Development, Attention, and Inhibition Study
NA trial testing Delay of Gratification in The Ability to Delay Gratification in 200 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | University of California, Davis |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 200 |
| Start date | 21 August 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Delay of Gratification
Conditions studied
- The Ability to Delay Gratification — all drugs for The Ability to Delay Gratification →
Sponsor
University of California, Davis
Who can join
Adults 4 to 7, any sex, with The Ability to Delay Gratification. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to test the associations of young children's early life experiences with delaying behaviors and links with later life outcomes. The main questions it aims to answer are: * Do experiences with waiting in early childhood predict delaying behavior in context-specific ways? * Are links between delaying behavior and life outcomes impacted by social conventions, effort and choices around delaying, or other behaviors? Participants will: * Complete two delaying tasks with either a sweet or wrapped gift * Complete three "Simon says"-like games that measure inhibition, cognitive flexibility and proactive control * Answer a set of questions about academic readiness * Answer a set of questions about social conventions * Complete a waiting game on the computer while a camera records eye movements * Parents will answer questions about their child's behaviors and experiences at home * Participants will return after 1 year to repeat a subset of these measures
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06605001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of California, Davis trials
Trials by the same sponsor.
- NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
- NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
- NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
- NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
- NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06605001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06605001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing